Cyclophosphamide–Bortezomib–Dexamethasone Compared with Bortezomib–Dexamethasone in Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma | Zendy

Amarilis Figueiredo | Zendy; Harold Atkins | Zendy; Ranjeeta Mallick | Zendy; Natasha Kekre | Zendy; Andrea Kew | Zendy; Arleigh McCurdy | Zendy

Open Access

Cyclophosphamide–Bortezomib–Dexamethasone Compared with Bortezomib–Dexamethasone in Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma

Author(s) -

Amarilis Figueiredo,

Harold Atkins,

Ranjeeta Mallick,

Natasha Kekre,

Andrea Kew,

Arleigh McCurdy

Publication year - 2020

Publication title -

current oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.053

H-Index - 51

eISSN - 1718-7729

pISSN - 1198-0052

DOI - 10.3747/co.27.5385

Subject(s) - medicine , bortezomib , multiple myeloma , regimen , dexamethasone , cyclophosphamide , cohort , transplantation , autologous stem cell transplantation , surgery , oncology , gastroenterology , chemotherapy

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) is considered a standard induction regimen for transplant-eligible patients with newly diagnosed multiple myeloma (mm). It has not been prospectively compared with bortezomib-dexamethasone (Bor-Dex). We aimed to compare the efficacy of CyBorD and Bor-Dex induction in transplant-eligible patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research